Can a new injectable drug pass its first human safety test?

NCT ID NCT07767487

NEW Not yet recruiting Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This early-stage trial is testing an experimental drug called LY4226695 in healthy volunteers to see how safe it is and what side effects it might cause. Participants receive either the drug or a placebo, given as an injection under the skin or into a vein. The study also measures how the body absorbs, processes, and eliminates the drug. Results will help determine whether further testing in patients is warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY4226695, an experimental drug given by injection under the skin or into a vein
What this could lead to: If successful, this early study could pave the way for further testing of LY4226695 as a potential treatment for future conditions.
What could go wrong: This is a very early Phase 1 trial in a small number of healthy people, so it is primarily about safety and dosing. The drug may cause side effects, and its effectiveness for any disease is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

CenExel ACT

Anaheim, California, 92801, United States
Lilly Centre for Clinical Pharmacology

Singapore, 138623, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.